Elimination mechanisms of therapeutic monoclonal antibodies
Top Cited Papers
- 1 January 2006
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 11 (1-2) , 81-88
- https://doi.org/10.1016/s1359-6446(05)03638-x
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Pharmacokinetic aspects of biotechnology productsJournal of Pharmaceutical Sciences, 2004
- Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell CancerJournal of Clinical Oncology, 2004
- Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s diseaseGastroenterology, 2003
- TrastuzumabDrugs, 2002
- Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeysJournal of Allergy and Clinical Immunology, 2001
- Antibody humanization: a case of the ‘Emperor’s new clothes’?Immunology Today, 2000
- FcRECEPTOR BIOLOGYAnnual Review of Immunology, 1997
- Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in miceNature Genetics, 1997
- Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?Immunology Today, 1993
- Treatment of Refractory Immune Thrombocytopenic Purpura with an Anti-Fcγ-Receptor AntibodyNew England Journal of Medicine, 1986